🇺🇸 FDA
Patent

US 11377491

Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer

granted A61KA61K2039/505A61P

Quick answer

US patent 11377491 (Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer) held by The Board of Regents of the University of Texas System expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61P, A61P35/00, A61P35/02